Satellos Bioscience

MSLE · TORONTO

$6.42−$0.205 (−3.09%)TodayMarket closed · Oct 23, 4:10 PM ET

Prev close $6.63

Latest news

Press releaseOct 21, 7:00 AM ETGlobe Newswire
Satellos to Participate in Upcoming Investor Conferences
Press releaseOct 5, 7:00 AM ETGlobe Newswire
Satellos Granted Composition of Matter Patent for Forazapadin
Press releaseSep 30, 7:00 AM ETGlobe Newswire
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
Press releaseSep 24, 7:00 AM ETGlobe Newswire
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
Press releaseSep 15, 7:00 AM ETGlobe Newswire
Satellos to Present at the 31st Annual Congress of the World Muscle Society
Press releaseSep 9, 7:00 AM ETGlobe Newswire
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
Press releaseSep 1, 7:00 AM ETGlobe Newswire
Satellos to Participate in Upcoming Investor Conferences
Press releaseAug 13, 5:02 PM ETGlobe Newswire
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
NewsJul 8, 9:34 AM ETVandana Singh
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
Press releaseJul 8, 6:30 AM ETGlobe Newswire
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
Press releaseJun 29, 7:00 AM ETGlobe Newswire
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
NewsMay 15, 7:11 AM ET
Earnings Scheduled For May 15, 2026
Press releaseMar 27, 7:00 AM ETGlobe Newswire
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
NewsMar 18, 8:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsMar 10, 1:06 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
Press releaseFeb 24, 7:00 AM ETBusiness Wire
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Press releaseFeb 18, 7:00 AM ETBusiness Wire
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
Press releaseFeb 17, 7:00 AM ETBusiness Wire
Satellos to Participate in Upcoming Investor Conferences
Press releaseFeb 10, 7:00 AM ETBusiness Wire
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Press releaseFeb 9, 5:00 PM ETBusiness Wire
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters' Option to Purchase Additional Shares
Press releaseFeb 6, 8:30 AM ETBusiness Wire
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Satellos to Participate in Upcoming Investor Conferences

Satellos Granted Composition of Matter Patent for Forazapadin

Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy

Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development

Satellos to Present at the 31st Annual Congress of the World Muscle Society

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

Satellos to Participate in Upcoming Investor Conferences

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress

Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence

Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247

Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

Earnings Scheduled For May 15, 2026

Satellos Reports 2025 Financial Results and Highlights Recent Company Progress

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy

Satellos to Participate in Upcoming Investor Conferences

Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters' Option to Purchase Additional Shares

Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States